China has started cracking down on unlicensed production and sale of medicines similar to Novo Nordisk A/S’s blockbuster diabetes and obesity treatment, in a bid to curb a gray market that caters to growing demand for such therapies amid a global supply crunch.

At least a dozen experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, with the most advanced now in the third and final stage of testing.

However, the research found that exercising helped preserve bone loss. Experts said that the findings may apply to other GLP-1s, such as semaglutide, the active ingredient in Ozempic. A rapid drop in weight can result in a loss of bone density,

Shares of Novo Nordisk A/S fell after the Danish drugmaker reported mixed safety data on one of its next-generation weight-loss drugs.

By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN (Reuters) -Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental obesity pill monlunabant came in below market expectations.

Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that works differently than its already-popular weight loss drug Wegovy.